Q8IVF7
Gene name |
FMNL3 (FHOD3, FRL2, KIAA2014, WBP3) |
Protein name |
Formin-like protein 3 |
Names |
Formin homology 2 domain-containing protein 3, WW domain-binding protein 3, WBP-3 |
Species |
Homo sapiens (Human) |
KEGG Pathway |
hsa:91010 |
EC number |
|
Protein Class |
|

Descriptions
(Annotation from UniProt)
The DAD domain may regulate activation via by an autoinhibitory interaction with the N-terminus. This autoinhibition may be released upon competitive binding of an activated GTPase. The release of DAD may allow the FH2 domain to nucleate and elongate nonbranched actin filaments.
Autoinhibitory domains (AIDs)
Target domain |
27-468 (GBD/FH3 domain) |
Relief mechanism |
Partner binding |
Assay |
|
Accessory elements
No accessory elements
Autoinhibited structure

Activated structure

1 structures for Q8IVF7
Entry ID | Method | Resolution | Chain | Position | Source |
---|---|---|---|---|---|
AF-Q8IVF7-F1 | Predicted | AlphaFoldDB |
No variants for Q8IVF7
Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
---|---|---|---|---|---|
No variants for Q8IVF7 |
1 associated diseases with Q8IVF7
[MIM: 619079]: Inflammatory bowel disease 30 (IBD30)
A chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology and a multifactorial inheritance pattern. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous. It may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints. . Note=The disease may be caused by variants affecting the gene represented in this entry. A number of groups have studied the possible association between variant rs2043211 and inflammatory bowel disease (PubMed:17030188, PubMed:19319132, PubMed:23506543, PubMed:26462578). According to some studies involving a limited number of patients, this variant is associated with inflammatory bowel disease (PubMed:17030188, PubMed:19319132, PubMed:23506543). Such association is however not confirmed in studies involving a large number of patients (PubMed:26462578). Discrepancies between studies may be caused by the variable consequences of this polymorphism in the different isoforms (PubMed:29408806). Whereas rs2043211 introduces a stop codon after 'Cys-10' (Cys10Ter) in isoform 1, and therefore the likely formation of a downstream transcriptional start site for this isoform, it causes Ile-102 variation in isoform 5, due to the upstream start site (PubMed:29408806). Moreover, most patients bearing this polymorphism continue to express the slightly smaller but fully functional isoform 7, as a result of transcription downstream of the rs2043211 polymorphism (PubMed:29408806). .
Without disease ID
- A chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology and a multifactorial inheritance pattern. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous. It may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints. . Note=The disease may be caused by variants affecting the gene represented in this entry. A number of groups have studied the possible association between variant rs2043211 and inflammatory bowel disease (PubMed:17030188, PubMed:19319132, PubMed:23506543, PubMed:26462578). According to some studies involving a limited number of patients, this variant is associated with inflammatory bowel disease (PubMed:17030188, PubMed:19319132, PubMed:23506543). Such association is however not confirmed in studies involving a large number of patients (PubMed:26462578). Discrepancies between studies may be caused by the variable consequences of this polymorphism in the different isoforms (PubMed:29408806). Whereas rs2043211 introduces a stop codon after 'Cys-10' (Cys10Ter) in isoform 1, and therefore the likely formation of a downstream transcriptional start site for this isoform, it causes Ile-102 variation in isoform 5, due to the upstream start site (PubMed:29408806). Moreover, most patients bearing this polymorphism continue to express the slightly smaller but fully functional isoform 7, as a result of transcription downstream of the rs2043211 polymorphism (PubMed:29408806). .
5 regional properties for Q8IVF7
Type | Name | Position | InterPro Accession |
---|---|---|---|
domain | CRIB domain | 10 - 62 | IPR000095 |
domain | Protein kinase domain | 448 - 699 | IPR000719 |
binding_site | Protein kinase, ATP binding site | 454 - 478 | IPR017441 |
domain | Serine/threonine-protein kinase PAK5, catalytic domain | 425 - 716 | IPR028754 |
domain | p21 activated kinase binding domain | 9 - 55 | IPR033923 |
5 GO annotations of cellular component
Name | Definition |
---|---|
cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
Golgi apparatus | A membrane-bound cytoplasmic organelle of the endomembrane system that further processes the core oligosaccharides (e.g. N-glycans) added to proteins in the endoplasmic reticulum and packages them into membrane-bound vesicles. The Golgi apparatus operates at the intersection of the secretory, lysosomal, and endocytic pathways. |
intracellular membrane-bounded organelle | Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane and occurring within the cell. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane. |
plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
3 GO annotations of molecular function
Name | Definition |
---|---|
actin filament binding | Binding to an actin filament, also known as F-actin, a helical filamentous polymer of globular G-actin subunits. |
GTPase activating protein binding | Binding to a GTPase activating protein. |
small GTPase binding | Binding to a small monomeric GTPase. |
5 GO annotations of biological process
Name | Definition |
---|---|
angiogenesis | Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels. |
cell migration | The controlled self-propelled movement of a cell from one site to a destination guided by molecular cues. Cell migration is a central process in the development and maintenance of multicellular organisms. |
cortical actin cytoskeleton organization | A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of actin-based cytoskeletal structures in the cell cortex, i.e. just beneath the plasma membrane. |
cytoskeleton organization | A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures. |
regulation of cell shape | Any process that modulates the surface configuration of a cell. |
6 homologous proteins in AiPD
UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
---|---|---|---|---|
Q9VUC6 | Frl | Formin-like protein | Drosophila melanogaster (Fruit fly) | EV |
O95466 | FMNL1 | Formin-like protein 1 | Homo sapiens (Human) | SS |
Q96PY5 | FMNL2 | Formin-like protein 2 | Homo sapiens (Human) | SS |
A2APV2 | Fmnl2 | Formin-like protein 2 | Mus musculus (Mouse) | SS |
Q9JL26 | Fmnl1 | Formin-like protein 1 | Mus musculus (Mouse) | SS |
Q6ZPF4 | Fmnl3 | Formin-like protein 3 | Mus musculus (Mouse) | SS |
10 | 20 | 30 | 40 | 50 | 60 |
MGNLESAEGV | PGEPPSVPLL | LPPGKMPMPE | PCELEERFAL | VLSSMNLPPD | KARLLRQYDN |
70 | 80 | 90 | 100 | 110 | 120 |
EKKWDLICDQ | ERFQVKNPPH | TYIQKLQSFL | DPSVTRKKFR | RRVQESTKVL | RELEISLRTN |
130 | 140 | 150 | 160 | 170 | 180 |
HIGWVREFLN | DENKGLDVLV | DYLSFAQCSV | MFDFEGLESG | DDGAFDKLRS | WSRSIEDLQP |
190 | 200 | 210 | 220 | 230 | 240 |
PSALSAPFTN | SLARSARQSV | LRYSTLPGRR | ALKNSRLVSQ | KDDVHVCILC | LRAIMNYQYG |
250 | 260 | 270 | 280 | 290 | 300 |
FNLVMSHPHA | VNEIALSLNN | KNPRTKALVL | ELLAAVCLVR | GGHEIILAAF | DNFKEVCKEL |
310 | 320 | 330 | 340 | 350 | 360 |
HRFEKLMEYF | RNEDSNIDFM | VACMQFINIV | VHSVEDMNFR | VHLQYEFTKL | GLEEFLQKSR |
370 | 380 | 390 | 400 | 410 | 420 |
HTESEKLQVQ | IQAYLDNVFD | VGGLLEDAET | KNVALEKVEE | LEEHVSHLTE | KLLDLENENM |
430 | 440 | 450 | 460 | 470 | 480 |
MRVAELEKQL | LQREKELESI | KETYENTSHQ | VHTLRRLIKE | KEEAFQRRCH | LEPNVRGLES |
490 | 500 | 510 | 520 | 530 | 540 |
VDSEALARVG | PAELSEGMPP | SDLDLLAPAP | PPEEVLPLPP | PPAPPLPPPP | PPLPDKCPPA |
550 | 560 | 570 | 580 | 590 | 600 |
PPLPGAAPSV | VLTVGLSAIR | IKKPIKTKFR | LPVFNWTALK | PNQISGTVFS | ELDDEKILED |
610 | 620 | 630 | 640 | 650 | 660 |
LDLDKFEELF | KTKAQGPALD | LICSKNKTAQ | KAASKVTLLE | ANRAKNLAIT | LRKAGRSAEE |
670 | 680 | 690 | 700 | 710 | 720 |
ICRAIHTFDL | QTLPVDFVEC | LMRFLPTEAE | VKLLRQYERE | RQPLEELAAE | DRFMLLFSKV |
730 | 740 | 750 | 760 | 770 | 780 |
ERLTQRMAGM | AFLGNFQDNL | QMLTPQLNAI | IAASASVKSS | QKLKQMLEII | LALGNYMNSS |
790 | 800 | 810 | 820 | 830 | 840 |
KRGAVYGFKL | QSLDLLLDTK | STDRKMTLLH | FIALTVKEKY | PDLANFWHEL | HFVEKAAAVS |
850 | 860 | 870 | 880 | 890 | 900 |
LENVLLDVKE | LGRGMELIRR | ECSIHDNSVL | RNFLSTNEGK | LDKLQRDAKT | AEEAYNAVVR |
910 | 920 | 930 | 940 | 950 | 960 |
YFGESPKTTP | PSVFFPVFVR | FIRSYKEAEQ | ENEARKKQEE | VMREKQLAQE | AKKLDAKTPS |
970 | 980 | 990 | 1000 | 1010 | 1020 |
QRNKWQQQEL | IAELRRRQAK | EHRPVYEGKD | GTIEDIITVL | KSVPFTARTA | KRGSRFFCDA |
AHHDESNC |